The following is a review of diagnostics related medical research worldwideThe information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.
The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Research News for May 2002
Researchers at the University of Louisville, Kentucky are developing a blood test may one day help doctors detect ovarian and uterine cancers at earlier, more treatable stages than is currently possible. The test detects membrane fragments from tumors that have been shed into the blood. The study involved more than 175 women who were healthy or had benign or malignant ovarian disease or early- or late-stage uterine cancer. When the researchers took blood samples from the women, they found tumor membrane fragments in those with both ovarian and uterine cancers. In addition, women with late-stage uterine cancer had more membrane fragments in their blood than women with early-stage disease. No membrane fragments were found in healthy women or those with benign ovarian disease, results showed. The study also found that certain proteins that have previously been associated with these cancers--MMP-2, MMP-9 and Fas ligand--were present on the membrane fragments.
The US Centers for Disease Control and Prevention (CDC) has issued new guidelines designed to help healthcare providers determine how often their patients should be screened for sexually transmitted diseases (STDs). Under the new guidelines, doctors are urged to screen all sexually active adolescent and young adult women up to 24 years old for chlamydia annually. Women older than 24 who have multiple partners should also be screened for chlamydia every year, the CDC recommends, and women who have been infected should be rescreened 3 to 4 months after completing treatment.
Researchers at Massachusetts General Hospital are developing an early warning test for pre-eclampsia. They have found that women who eventually develop pre-eclampsia are more likely to have reduced blood levels of sex hormone binding globulin (SHBG). The study is part of the hospital's Obstetrical Maternal Study, a prospective study of more than 4,500 women looking to identify risk factors for hypertensive disorders of pregnancy.
Research News - April 2002
Product Developments Worldwide | Research News | Health Care in Canada
Information Technology and Healthcare | Molecular Biology | Links
Send mail to email@example.com with questions or comments about this web site.
Concept and Design Blue Page
Last modified: June 01, 2002